Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -20.01% is 50% above its 5-year average of -39.69%, near the high end of its 5-year range (-76.08%–-20.01%).
47.61% above its 12-month average of -38.20%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -2.66%.
RETURN ON ASSETS (ROA)
-20.01%
RETURN ON ASSETS (ROA) AVG TTM
-38.20%
RETURN ON ASSETS (ROA) AVG 3Y
-34.64%
RETURN ON ASSETS (ROA) AVG 5Y
-39.69%
RETURN ON ASSETS (ROA) AVG 10Y
-63.21%
RETURN ON ASSETS (ROA) AVG 15Y
-70.82%
RETURN ON ASSETS (ROA) AVG 20Y
-564.83%
CURRENT VS TTM AVG
+47.61%
CURRENT VS 3Y AVG
+42.24%
CURRENT VS 5Y AVG
+49.58%
CURRENT VS 10Y AVG
+68.34%
CURRENT VS 15Y AVG
+71.75%
CURRENT VS 20Y AVG
+96.46%
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 819 covered companies
CURRENT VS SECTOR MEDIAN
+37.10%
vs the sector median at left
Anavex Life Sciences Corp.
Market Cap
$145.55M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$145.54M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$144.19M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$147.95M
Return on Assets (ROA)
-76.12%
TTM Avg
-156.63%
3Y Avg
-142.29%
5Y Avg
-134.64%
Market Cap
$143.10M
Return on Assets (ROA)
-59.36%
TTM Avg
-56.73%
3Y Avg
-42.41%
5Y Avg
-32.43%
Market Cap
$142.48M
Return on Assets (ROA)
-39.76%
TTM Avg
-26.00%
3Y Avg
-40.35%
5Y Avg
-34.25%
Market Cap
$141.82M
Return on Assets (ROA)
-92.89%
TTM Avg
-84.34%
3Y Avg
-55.16%
5Y Avg
-43.29%
Market Cap
$149.36M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$149.51M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $145.55M | -20.01% | -38.20% | -34.64% | -39.69% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | -90.55% | -70.80% | -45.07% | -40.08% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.19M | -96.78% | -33.63% | -87.61% | -84.15% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.95M | -76.12% | -156.63% | -142.29% | -134.64% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -59.36% | -56.73% | -42.41% | -32.43% |
| Protara Therapeutics, Inc. (TARA)vs › | $142.48M | -39.76% | -26.00% | -40.35% | -34.25% |
| Sutro Biopharma, Inc. (STRO)vs › | $141.82M | -92.89% | -84.34% | -55.16% | -43.29% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -50.30% | -131.74% | -92.52% | -67.08% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -25.59% | -36.78% | -35.70% | -27.05% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.85M | -127.14% | -129.15% | -91.50% | -82.73% |
ROA
-20.0%
ROE
-21.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -44.67% |
| 2024-09-30 | -31.72% |
| 2023-09-30 | -30.77% |
| 2022-09-30 | -31.42% |
| 2021-09-30 | -23.46% |
| 2020-09-30 | -76.08% |
| 2019-09-30 | -103.81% |
| 2018-09-30 | -71.60% |
| 2017-09-30 | -48.35% |
| 2016-09-30 | -155.14% |
| 2015-09-30 | -78.27% |
| 2014-09-30 | -154.60% |
| 2013-09-30 | -940.41% |
| 2012-09-30 | -63116.44% |
| 2011-09-30 | -3598.89% |
| 2010-09-30 | -2662.74% |
| 2009-09-30 | -1345.78% |
| 2008-09-30 | -74127.57% |
| 2007-09-30 | -6319972.00% |
| 2006-09-30 | -204.34% |
| 2005-09-30 | -9378.20% |
| 2004-09-30 | -51.21% |
